

# Yong-Tae Kim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7512604/publications.pdf>

Version: 2024-02-01

82  
papers

1,283  
citations

448610

19  
h-index

466096

32  
g-index

86  
all docs

86  
docs citations

86  
times ranked

2345  
citing authors

#	ARTICLE	IF	CITATIONS
1	Four-Tier Pathologic Tumor Regression Grading System Predicts the Clinical Outcome in Patients Who Undergo Surgical Resection for Locally Advanced Pancreatic Cancer after Neoadjuvant Chemotherapy. <i>Gut and Liver</i> , 2022, 16, 129-137.	1.4	2
2	Real-World Outcomes of Gemcitabine, Cisplatin, and Nab-Paclitaxel Chemotherapy Regimen for Advanced Biliary Tract Cancer: A Propensity Score-Matched Analysis. <i>Gut and Liver</i> , 2022, 16, 798-805.	1.4	3
3	Tumor resectability and response on CT following neoadjuvant therapy for pancreatic cancer: inter-observer agreement study. <i>European Radiology</i> , 2022, 32, 3799-3807.	2.3	4
4	Prediction model using clinical factors for radiation exposure during endoscopic retrograde cholangiopancreatography. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1342-1348.	1.4	1
5	Transhepatic stent placement for malignant portal vein obstruction: Long term efficacy and factors associated with stent failure. <i>European Journal of Radiology</i> , 2022, 149, 110230.	1.2	1
6	Downregulation of ASF1B inhibits tumor progression and enhances efficacy of cisplatin in pancreatic cancer. <i>Cancer Biomarkers</i> , 2022, 34, 647-659.	0.8	7
7	Multi-Phase, Contrast-Enhanced Computed Tomography-Based Radiomic Prognostic Marker of Non-Metastatic Pancreatic Ductal Adenocarcinoma. <i>Cancers</i> , 2022, 14, 2476.	1.7	3
8	Planned and actual dose reduction of standard or modified FOLFIRINOX in metastatic pancreatic cancer: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16279-e16279.	0.8	0
9	The clinical significance of preoperative C-reactive protein/albumin ratio in patients with resected extrahepatic bile duct cancer. <i>Surgery Today</i> , 2021, 51, 978-985.	0.7	3
10	Gastrointestinal Bleeding Of Unknown Origin In Patients With Splenic Aneurysm. <i>Clinical Endoscopy</i> , 2021, 54, 293-294.	0.6	0
11	Tailored adjuvant gemcitabine versus 5-fluorouracil/folinic acid based on hENT1 immunohistochemical staining in resected pancreatic ductal adenocarcinoma: A biomarker stratified prospective trial. <i>Pancreatology</i> , 2021, 21, 796-804.	0.5	2
12	Maintenance of skeletal muscle mass during FOLFIRINOX is a favorable prognostic factor in pancreatic cancer patients. <i>BMC Research Notes</i> , 2021, 14, 272.	0.6	8
13	Abstract 248: A novel PubMed visualizer using human-computer interaction technology: EEEvis.com. , 2021, , .		0
14	Clinical Impact of Unexpected Para-Aortic Lymph Node Metastasis in Surgery for Resectable Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 4454.	1.7	1
15	Gender Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX. <i>Journal of Personalized Medicine</i> , 2021, 11, 83.	1.1	8
16	Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2021, 11, 20152.	1.6	11
17	A prospective, randomized, multicenter clinical trial comparing 25-gauge and 20-gauge biopsy needles for endoscopic ultrasound-guided sampling of solid pancreatic lesions. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2020, 34, 1310-1317.	1.3	10
18	Clinical Factors Associated With Gastric Cancer in Individuals With Lynch Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 830-837.e1.	2.4	38

#	ARTICLE	IF	CITATIONS
19	Serum fibrinogen as a diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma. <i>Pancreatology</i> , 2020, 20, 1465-1471.	0.5	15
20	Postoperative muscle mass restoration as a prognostic factor in patients with resected pancreatic cancer. <i>PLoS ONE</i> , 2020, 15, e0238649.	1.1	3
21	Cdc6 disruption leads to centrosome abnormalities and chromosome instability in pancreatic cancer cells. <i>Scientific Reports</i> , 2020, 10, 16518.	1.6	12
22	High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer. <i>Scientific Reports</i> , 2020, 10, 12348.	1.6	48
23	A multicenter prospective randomized controlled trial for preoperative biliary drainage with uncovered metal versus plastic stents for resectable periampullary cancer. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2020, 27, 690-699.	1.4	8
24	Involvement of the NF- $\kappa$ B signaling pathway in proliferation and invasion inhibited by Zwint-1 deficiency in Pancreatic Cancer Cells. <i>Journal of Cancer</i> , 2020, 11, 5601-5611.	1.2	9
25	Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 654-659.	0.6	18
26	Primary Granulocyte Colony-Stimulating Factor Prophylaxis in Metastatic Pancreatic Cancer Patients Treated with FOLFIRINOX as the First-Line Treatment. <i>Cancers</i> , 2020, 12, 3137.	1.7	10
27	Gemcitabine Plus Cisplatin Chemotherapy Prolongs the Survival in Advanced Hilar Cholangiocarcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 422-427.	0.6	12
28	The American Joint Committee on Cancer 8th edition staging system for the pancreatic ductal adenocarcinoma: is it better than the 7th edition?. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 98-100.	0.7	7
29	Innovation of EUS-guided transmural gallbladder drainage using a novel self-expanding metal stent. <i>Scientific Reports</i> , 2020, 10, 11159.	1.6	2
30	Tolerability and safety of EUS-injected adenovirus-mediated double-suicide gene therapy with chemotherapy in locally advanced pancreatic cancer: a phase 1 trial. <i>Gastrointestinal Endoscopy</i> , 2020, 92, 1044-1052.e1.	0.5	43
31	Higher Tumor Cellularity in Resected Pancreatic Ductal Adenocarcinoma Is a Negative Prognostic Indicator. <i>Gut and Liver</i> , 2020, 14, 521-528.	1.4	6
32	Recent 5-Year Trend of Endoscopic Retrograde Cholangiography in Korea Using National Health Insurance Review and Assessment Service Open Data. <i>Gut and Liver</i> , 2020, 14, 833-841.	1.4	9
33	Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer according to intention-to-treat and per-protocol analysis: A systematic review and meta-analysis. <i>Scientific Reports</i> , 2019, 9, 15662.	1.6	38
34	Validation of the American Joint Committee on Cancer 8th edition staging system for the pancreatic ductal adenocarcinoma. <i>European Journal of Surgical Oncology</i> , 2019, 45, 2159-2165.	0.5	27
35	Same-session endoscopic ultrasound-guided fine needle aspiration and endoscopic retrograde cholangiopancreatography-based tissue sampling in suspected malignant biliary obstruction: A multicenter experience. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 799-805.	1.4	32
36	Tolerability and safety of a replication-competent adenovirus-mediated double suicide gene therapy (Ad5-yCD/mutTK(SR39)rep-ADP) with chemotherapy in locally advanced pancreatic cancer: Phase 1 trial. <i>Journal of Clinical Oncology</i> , 2019, 37, e15761-e15761.	0.8	2

#	ARTICLE	IF	CITATIONS
37	Comparison of FOLFIRINOX and gemcitabine with nab-paclitaxel in metastatic pancreatic cancer: Using Korean Pancreatic Cancer (K-PaC) Registry.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15762-e15762.	0.8	1
38	Enhancements in pancreatic protocol CT as a prognostic indicator in pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 216-216.	0.8	1
39	Management of recurrent pancreatic cancer after surgical resection: a protocol for systematic review, evidence mapping and meta-analysis. <i>BMJ Open</i> , 2018, 8, e017249.	0.8	22
40	Clinical outcomes of endoscopic ultrasound-guided ethanol ablation for pancreatic cystic lesions compared with the natural course: a propensity score matching analysis. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481875992.	1.4	17
41	Optimal time of resuming anticoagulant after endoscopic sphincterotomy in patients at risk for thromboembolism: a retrospective cohort study. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2018, 32, 3902-3908.	1.3	7
42	Clinical outcomes of FOLFIRINOX in locally advanced pancreatic cancer. <i>Medicine (United States)</i> , 2018, 97, e13592.	0.4	21
43	Effect of submucosal injection in endoscopic papillectomy of ampullary tumor: Propensity score matching analysis. <i>United European Gastroenterology Journal</i> , 2018, 6, 576-585.	1.6	21
44	Predictive factors of therapeutic intervention in on-call endoscopy for suspected gastrointestinal bleeding. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 958-963.	0.6	0
45	It is necessary to exam bottom and top slide smears of EUS-FNA for pancreatic cancer. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2018, 17, 553-558.	0.6	1
46	Outcome of endoscopic retrograde cholangiopancreatography in patients with clinically defined decompensated liver cirrhosis. <i>Journal of Digestive Diseases</i> , 2018, 19, 605-613.	0.7	4
47	Adjunctive role of preoperative liver magnetic resonance imaging for potentially resectable pancreatic cancer. <i>Surgery</i> , 2017, 161, 1579-1587.	1.0	37
48	Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity. <i>European Journal of Cancer</i> , 2017, 76, 125-133.	1.3	38
49	The prognostic significance of cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. <i>Tumor Biology</i> , 2017, 39, 101042831771840.	0.8	39
50	Effect of Combinatory Treatment With Resveratrol and Guggulsterone on Mild Acute Pancreatitis in Mice. <i>Pancreas</i> , 2017, 46, 366-371.	0.5	8
51	Percutaneous transhepatic versus EUS-guided gallbladder drainage for malignant cystic duct obstruction. <i>Gastrointestinal Endoscopy</i> , 2017, 85, 357-364.	0.5	54
52	Early versus delayed initiation of adjuvant treatment for pancreatic cancer. <i>PLoS ONE</i> , 2017, 12, e0173960.	1.1	21
53	Combination immunohistochemistry for SMAD4 and Runt-related transcription factor 3 may identify a favorable prognostic subgroup of pancreatic ductal adenocarcinomas. <i>Oncotarget</i> , 2017, 8, 76699-76711.	0.8	2
54	Development of a nomogram for screening of hepatitis B virus-associated hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 106499-106510.	0.8	5

#	ARTICLE	IF	CITATIONS
55	Training in Endoscopy: Endoscopic Retrograde Cholangiopancreatography. <i>Clinical Endoscopy</i> , 2017, 50, 334-339.	0.6	11
56	Clinical outcomes of FOLFIRINOX in locally advanced pancreatic cancer: A single center experience.. <i>Journal of Clinical Oncology</i> , 2017, 35, 480-480.	0.8	0
57	Management of recurrent pancreatic cancer after surgical resection: Systematic review, evidence mapping, and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, 448-448.	0.8	0
58	Clinical impact of neoadjuvant treatment in resectable pancreatic cancer: a systematic review and meta-analysis protocol. <i>BMJ Open</i> , 2016, 6, e010491.	0.8	8
59	A Case of Idiopathic Severe Acute Pancreatitis following Cesarean Section Delivery. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2016, 68, 161.	0.2	1
60	Predictors of Increased Risk of Hepatocellular Carcinoma in Patients with Type 2 Diabetes. <i>PLoS ONE</i> , 2016, 11, e0158066.	1.1	12
61	Early decrement of serum carbohydrate antigen 19â€9 predicts favorable outcome in advanced pancreatic cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 506-512.	1.4	15
62	The minimal effective relative dose intensity (RDI) for modified FOLFIRINOX in advanced pancreatic cancer: Suggestion for modified Hryniukâ€™s calculation method.. <i>Journal of Clinical Oncology</i> , 2016, 34, 402-402.	0.8	1
63	Optimizing Surveillance Performance of Alpha-Fetoprotein by Selection of Proper Target Population in Chronic Hepatitis B. <i>PLoS ONE</i> , 2016, 11, e0168189.	1.1	7
64	Effects of N-acetylcysteine on First-Line Sequential Therapy for Helicobacter pylori Infection: A Randomized Controlled Pilot Trial. <i>Gut and Liver</i> , 2016, 10, 520-525.	1.4	10
65	Adjunctive role of preoperative liver magnetic resonance imaging added to computed tomography among resected pancreatic cancer patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 207-207.	0.8	0
66	Presence of pancreatic intraepithelial neoplasiaâ€³ in a background of chronic pancreatitis in pancreatic cancer patients. <i>Cancer Science</i> , 2015, 106, 1408-1413.	1.7	9
67	Effect of vitamin E in nonalcoholic fatty liver disease with metabolic syndrome: A propensity score-matched cohort study. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 379.	4.5	17
68	Postoperative Carcinoembryonic Antigen as a Complementary Tumor Marker of Carbohydrate Antigen 19-9 in Pancreatic Ductal Adenocarcinoma. <i>Journal of Korean Medical Science</i> , 2015, 30, 259.	1.1	15
69	Postoperative early thromboembolism as a prognostic indicator in patients with curatively resected pancreatic cancer. <i>American Journal of Surgery</i> , 2015, 210, 871-877.	0.9	1
70	Optimal initiation of <i>Helicobacter pylori</i> eradication in patients with peptic ulcer bleeding. <i>World Journal of Gastroenterology</i> , 2015, 21, 2497.	1.4	8
71	Endoscopic Ultrasound-Guided Treatment of Pancreatic Cystic and Solid Masses. <i>Clinical Endoscopy</i> , 2015, 48, 308.	0.6	18
72	Angiolipoma of the stomach presenting with anaemia. <i>Przegląd Gastroenterologiczny</i> , 2014, 6, 371-374.	0.3	6

#	ARTICLE	IF	CITATIONS
73	Effect of sustained use of platelet aggregation inhibitors on post-ERCP sphincterotomy bleeding. <i>Digestive Endoscopy</i> , 2014, 26, 737-744.	1.3	20
74	Infliximol Reduces Severity of Acute Pancreatitis by Inhibiting Nuclear Factor- $\kappa$ B Activation in Cerulein-Induced Pancreatitis. <i>Pancreas</i> , 2013, 42, 279-284.	0.5	8
75	Clinical Significance and Revisiting the Meaning of CA 19-9 Blood Level Before and After the Treatment of Pancreatic Ductal Adenocarcinoma: Analysis of 1,446 Patients from the Pancreatic Cancer Cohort in a Single Institution. <i>PLoS ONE</i> , 2013, 8, e78977.	1.1	34
76	Endoscopic Papillectomy for Benign Ampullary Neoplasms: How Can Treatment Outcome Be Predicted?. <i>Gut and Liver</i> , 2013, 7, 239-245.	1.4	20
77	The Role of Quantitative NPTX2 Hypermethylation as a Novel Serum Diagnostic Marker in Pancreatic Cancer. <i>Pancreas</i> , 2012, 41, 95-101.	0.5	44
78	Long-Term Outcome of Cystic Lesions in the Pancreas: A Retrospective Cohort Study. <i>Gut and Liver</i> , 2012, 6, 493-500.	1.4	13
79	Cyst Growth Rate Predicts Malignancy in Patients With Branch Duct Intraductal Papillary Mucinous Neoplasms. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 87-93.	2.4	192
80	Feasibility of endoscopic papillectomy in early stage ampulla of Vater cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 120-124.	1.4	51
81	Effects of Nafamostat Mesilate on the Prevention of Cerulein-Induced Acute Pancreatitis. <i>Pancreas</i> , 2008, 36, 255-260.	0.5	7
82	Outcomes of Cystic Lesions in the Pancreas After Extended Follow-up. <i>Digestive Diseases and Sciences</i> , 2007, 52, 2653-2659.	1.1	49